Trial Profile
Phase III clinical trial programme for KD 019
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 13 Nov 2007
Price :
$35
*
At a glance
- Drugs Tesevatinib (Primary)
- Indications Cancer
- Focus Registrational; Therapeutic Use
- Sponsors Exelixis
- 13 Nov 2007 New trial record.